Eadie, L.Hughes, T.White, D.2014-10-282014-10-282014Clinical Pharmacology and Therapeutics, 2014; 95(3):294-3060009-92361532-6535http://hdl.handle.net/2440/86734The efflux transporters adenosine triphosphate (ATP)-binding cassette (ABC)B1 and ABCG2 have been demonstrated to interact with the tyrosine kinase inhibitors (TKIs) imatinib, nilotinib, and dasatinib. However, although some studies conclude that TKIs are substrates of one or both transporters, other studies demonstrate only an inhibitory function. This variation is probably due to differences in the concentration of TKIs assayed and the experimental systems used. This article examines the evidence for clinically relevant interactions between three currently approved TKIs and ABCB1/ABCG2.en© 2014 American Society for Clinical Pharmacology and TherapeuticsAnimalsHumansBenzamidesPiperazinesPyrimidinesThiazolesATP-Binding Cassette TransportersNeoplasm ProteinsEnzyme InhibitorsProtein-Tyrosine KinasesImatinib MesylateDasatinibATP Binding Cassette Transporter, Subfamily G, Member 2ATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Journal article002013564710.1038/clpt.2013.2080003318866000192-s2.0-8489441352316031Eadie, L. [0000-0003-1912-7602]Hughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509]White, D. [0000-0003-4844-333X]